Pseudomonas aeruginosa aggregation and Psl expression in sputum is associated with antibiotic eradication failure in children with cystic fibrosis.

Abstract

We previously demonstrated that P. aeruginosa isolates that persisted in children with cystic fibrosis (CF) despite inhaled tobramycin treatment had increased anti-Psl antibody binding in vitro compared to those successfully eradicated. We aimed to validate these findings by directly visualizing P. aeruginosa in CF sputum. This was a prospective observational study of children with CF with new-onset P. aeruginosa infection who underwent inhaled tobramycin eradication treatment. Using microbial identification passive clarity technique (MiPACT), P. aeruginosa was visualized in sputum samples obtained before treatment and classified as persistent or eradicated based on outcomes. Pre-treatment isolates were also grown as biofilms in vitro. Of 11 patients enrolled, 4 developed persistent infection and 7 eradicated infection. P. aeruginosa biovolume and the number as well as size of P. aeruginosa aggregates were greater in the sputum of those with persistent compared with eradicated infections (p < 0.01). The amount of Psl antibody binding in sputum was also greater overall (p < 0.05) in samples with increased P. aeruginosa biovolume. When visualized in sputum, P. aeruginosa had a greater biovolume, with more expressed Psl, and formed more numerous, larger aggregates in CF children who failed eradication therapy compared to those who successfully cleared their infection.

• Authors: Amanda J Morris, Yvonne C W Yau, Subin Park, Shafinaz Eisha, Nancy McDonald, Matthew R Parsek, P Lynne Howell, Lucas R Hoffman, Dao Nguyen, Antonio DiGiandomenico, Ashley M Rooney, Bryan Coburn, Lucia Grana-Miraglia, Pauline Wang, David S Guttman, Daniel J Wozniak, Valerie J Waters
• Journal: Scientific reports (Sci Rep) Vol. 12 Issue 1 Pg. 21444 (12 12 2022) ISSN: 2045-2322 [Electronic] England
• PMID: 36509824 (Publication Type: Observational Study, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2022. The Author(s).

Chemical References

• Anti-Bacterial Agents
• Tobramycin

Topics

• Child
• Humans
• Pseudomonas aeruginosa (metabolism)
• Cystic Fibrosis (complications, drug therapy)
• Anti-Bacterial Agents (pharmacology, therapeutic use)
• Pseudomonas Infections (drug therapy, complications)
• Tobramycin (therapeutic use, metabolism)
• Sputum